In the News: Several ICRF-Funded Researchers Highlighted in The Jerusalem Post

A Jerusalem Post article highlighting Tel Aviv University’s multidisciplinary approach to cancer research features several scientists whose work has been supported by ICRF, including current grantees and former grant recipients.

Among those featured is current ICRF grantee Prof. Uri Ben-David, whose research examines how cancer cells adapt to abnormal chromosome numbers. He recently received the 2026 Blavatnik Award for Young Scientists in Israel in Life Sciences in recognition of his research accomplishments.

Also featured is current ICRF grantee Prof. Adit Ben-Baruch, who studies how inflammation and interactions between cancer cells and their surrounding environment contribute to breast cancer growth and spread, with the goal of identifying new targets for more personalized treatments.

Former ICRF grantees Prof. Ronit Satchi-Fainaro and Prof. Dan Peer are also featured. Satchi-Fainaro develops nanomedicines and targeted drug-delivery systems to improve cancer treatment. Through an ICRF Research Professorship, she investigated P-selectin-targeted nanomedicines and immunotherapy to prevent brain metastases, including approaches to slowing glioblastoma progression. She received the 2025 NCK Prize for an Outstanding Medicinal Chemist for her contributions to anticancer therapeutics.

Peer develops nanomedicine technologies that deliver RNA-based therapies and gene-editing tools to specific cells. His past ICRF-funded research explored nanoparticle-based approaches to deliver gene-silencing treatments to brain tumors. In subsequent research, his team used targeted lipid nanoparticles to deliver CRISPR gene-editing tools to cancer cells, demonstrating promising results against metastatic cancer in mice.